 Matthew Sikora
Concepts (221)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Lobular | 10 | 2022 | 44 | 2.940 |
Why?
| | Breast Neoplasms | 23 | 2024 | 1862 | 2.650 |
Why?
| | Receptors, Estrogen | 9 | 2023 | 372 | 2.500 |
Why?
| | Wnt4 Protein | 4 | 2024 | 17 | 2.190 |
Why?
| | Estrogen Receptor alpha | 9 | 2023 | 121 | 1.420 |
Why?
| | Antineoplastic Agents, Hormonal | 5 | 2017 | 138 | 1.420 |
Why?
| | Estrogens | 6 | 2023 | 312 | 1.330 |
Why?
| | Drug Resistance, Neoplasm | 8 | 2019 | 636 | 1.010 |
Why?
| | Tamoxifen | 7 | 2021 | 191 | 0.850 |
Why?
| | Genital Neoplasms, Female | 1 | 2024 | 70 | 0.830 |
Why?
| | Genital Diseases, Female | 1 | 2021 | 25 | 0.750 |
Why?
| | MCF-7 Cells | 10 | 2021 | 105 | 0.740 |
Why?
| | Gene Expression Regulation, Neoplastic | 11 | 2023 | 1141 | 0.740 |
Why?
| | Genitalia, Female | 1 | 2021 | 37 | 0.740 |
Why?
| | Cell Proliferation | 12 | 2021 | 2187 | 0.730 |
Why?
| | Estradiol | 7 | 2023 | 455 | 0.730 |
Why?
| | Cell Line, Tumor | 16 | 2023 | 2710 | 0.710 |
Why?
| | Cell Cycle Proteins | 2 | 2021 | 551 | 0.690 |
Why?
| | Wnt3A Protein | 1 | 2019 | 7 | 0.680 |
Why?
| | Acyltransferases | 1 | 2019 | 46 | 0.670 |
Why?
| | Women's Health | 1 | 2021 | 271 | 0.640 |
Why?
| | Wnt Signaling Pathway | 2 | 2019 | 146 | 0.640 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2021 | 367 | 0.610 |
Why?
| | Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2017 | 25 | 0.570 |
Why?
| | Receptors, Mineralocorticoid | 1 | 2016 | 7 | 0.550 |
Why?
| | Ovarian Neoplasms | 5 | 2020 | 388 | 0.550 |
Why?
| | Signal Transduction | 8 | 2024 | 4515 | 0.520 |
Why?
| | Serum | 1 | 2016 | 57 | 0.520 |
Why?
| | Receptors, Androgen | 1 | 2016 | 131 | 0.500 |
Why?
| | Receptors, Glucocorticoid | 1 | 2016 | 130 | 0.500 |
Why?
| | Neoplasm Invasiveness | 6 | 2020 | 442 | 0.470 |
Why?
| | Receptors, Progesterone | 1 | 2016 | 319 | 0.470 |
Why?
| | Deep Brain Stimulation | 3 | 2020 | 72 | 0.470 |
Why?
| | Aromatase Inhibitors | 2 | 2018 | 49 | 0.450 |
Why?
| | Membrane Proteins | 1 | 2019 | 1019 | 0.440 |
Why?
| | Cytochrome P-450 CYP2D6 | 4 | 2017 | 24 | 0.380 |
Why?
| | Gene Expression | 2 | 2014 | 1421 | 0.370 |
Why?
| | Paraffin Embedding | 1 | 2010 | 21 | 0.350 |
Why?
| | Benzoxazines | 1 | 2010 | 28 | 0.350 |
Why?
| | Estrogen Antagonists | 1 | 2010 | 39 | 0.350 |
Why?
| | Genotyping Techniques | 1 | 2010 | 69 | 0.350 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2010 | 82 | 0.340 |
Why?
| | Female | 29 | 2024 | 59520 | 0.320 |
Why?
| | Humans | 38 | 2024 | 114698 | 0.310 |
Why?
| | Androstane-3,17-diol | 1 | 2008 | 2 | 0.310 |
Why?
| | Gossypol | 1 | 2008 | 1 | 0.310 |
Why?
| | Models, Biological | 2 | 2012 | 1621 | 0.300 |
Why?
| | Carcinoma, Ductal, Breast | 3 | 2022 | 76 | 0.270 |
Why?
| | Breast | 3 | 2022 | 139 | 0.260 |
Why?
| | Neoplasms | 2 | 2010 | 2097 | 0.250 |
Why?
| | Tumor Microenvironment | 2 | 2020 | 430 | 0.250 |
Why?
| | Receptor, ErbB-2 | 2 | 2019 | 300 | 0.250 |
Why?
| | Antioxidants | 1 | 2008 | 530 | 0.230 |
Why?
| | Carbonyl Reductase (NADPH) | 1 | 2024 | 4 | 0.230 |
Why?
| | DNA | 1 | 2010 | 1352 | 0.220 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2024 | 172 | 0.200 |
Why?
| | Selective Estrogen Receptor Modulators | 3 | 2017 | 26 | 0.200 |
Why?
| | Ligands | 1 | 2024 | 562 | 0.190 |
Why?
| | Sex Differentiation | 1 | 2021 | 11 | 0.190 |
Why?
| | Sexual Development | 1 | 2021 | 19 | 0.190 |
Why?
| | Protein Binding | 2 | 2016 | 1890 | 0.190 |
Why?
| | Mammary Glands, Human | 1 | 2021 | 60 | 0.180 |
Why?
| | Neuroma, Acoustic | 1 | 2021 | 33 | 0.180 |
Why?
| | RNA Interference | 2 | 2019 | 433 | 0.180 |
Why?
| | Genotype | 3 | 2017 | 1760 | 0.180 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2020 | 38 | 0.180 |
Why?
| | Uterus | 1 | 2021 | 192 | 0.170 |
Why?
| | Cell Survival | 2 | 2016 | 1021 | 0.170 |
Why?
| | Culture Media, Conditioned | 1 | 2019 | 105 | 0.170 |
Why?
| | Machine Learning | 2 | 2020 | 316 | 0.170 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2021 | 1880 | 0.160 |
Why?
| | Paracrine Communication | 1 | 2019 | 56 | 0.160 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2020 | 332 | 0.160 |
Why?
| | Coculture Techniques | 1 | 2019 | 201 | 0.160 |
Why?
| | Snail Family Transcription Factors | 1 | 2019 | 19 | 0.160 |
Why?
| | Gene Expression Profiling | 2 | 2018 | 1518 | 0.160 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2019 | 88 | 0.160 |
Why?
| | Gene Amplification | 1 | 2019 | 95 | 0.160 |
Why?
| | Phthalazines | 1 | 2019 | 38 | 0.160 |
Why?
| | Neoadjuvant Therapy | 1 | 2020 | 304 | 0.150 |
Why?
| | Transcriptome | 2 | 2021 | 725 | 0.150 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2019 | 68 | 0.150 |
Why?
| | Endometriosis | 1 | 2018 | 40 | 0.150 |
Why?
| | Protein Transport | 1 | 2019 | 395 | 0.150 |
Why?
| | Estrogen Receptor Antagonists | 1 | 2017 | 2 | 0.150 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2019 | 194 | 0.150 |
Why?
| | RNA, Small Interfering | 1 | 2019 | 535 | 0.140 |
Why?
| | Antineoplastic Agents | 1 | 2008 | 1879 | 0.140 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2019 | 388 | 0.140 |
Why?
| | Fishes | 1 | 2017 | 80 | 0.140 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2012 | 1842 | 0.140 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2017 | 38 | 0.140 |
Why?
| | Piperazines | 1 | 2019 | 309 | 0.140 |
Why?
| | Animals | 7 | 2021 | 31708 | 0.140 |
Why?
| | Promoter Regions, Genetic | 1 | 2021 | 1131 | 0.140 |
Why?
| | Surgical Wound Infection | 1 | 2019 | 248 | 0.140 |
Why?
| | Neoplasm Staging | 2 | 2017 | 1167 | 0.130 |
Why?
| | Androstenes | 1 | 2016 | 11 | 0.130 |
Why?
| | Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2016 | 11 | 0.130 |
Why?
| | Cell Culture Techniques | 1 | 2018 | 343 | 0.130 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2016 | 107 | 0.130 |
Why?
| | Polymorphism, Genetic | 2 | 2017 | 610 | 0.130 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2016 | 34 | 0.130 |
Why?
| | Algorithms | 2 | 2020 | 1470 | 0.130 |
Why?
| | Reproduction | 1 | 2017 | 178 | 0.130 |
Why?
| | Proto-Oncogene Proteins | 1 | 2019 | 608 | 0.130 |
Why?
| | Lipid Metabolism | 1 | 2018 | 444 | 0.130 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 1355 | 0.120 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2019 | 858 | 0.110 |
Why?
| | Biomarkers, Tumor | 2 | 2019 | 1040 | 0.110 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 916 | 0.110 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2014 | 48 | 0.110 |
Why?
| | Mutation | 2 | 2021 | 3346 | 0.110 |
Why?
| | Mice | 5 | 2021 | 14871 | 0.100 |
Why?
| | NF-kappa B | 1 | 2016 | 641 | 0.100 |
Why?
| | Postoperative Complications | 2 | 2021 | 2128 | 0.100 |
Why?
| | Smoking | 1 | 2019 | 1383 | 0.100 |
Why?
| | Phenotype | 2 | 2018 | 2796 | 0.100 |
Why?
| | Prognosis | 4 | 2020 | 3329 | 0.090 |
Why?
| | Gynecomastia | 1 | 2010 | 4 | 0.090 |
Why?
| | Formaldehyde | 1 | 2010 | 46 | 0.090 |
Why?
| | Inhibitory Concentration 50 | 1 | 2010 | 74 | 0.090 |
Why?
| | Cyclopropanes | 1 | 2010 | 81 | 0.090 |
Why?
| | Alkynes | 1 | 2010 | 53 | 0.090 |
Why?
| | Microarray Analysis | 1 | 2010 | 118 | 0.090 |
Why?
| | Inflammation | 1 | 2020 | 2480 | 0.090 |
Why?
| | Middle Aged | 7 | 2019 | 26738 | 0.090 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 923 | 0.080 |
Why?
| | Pregnancy | 1 | 2021 | 5520 | 0.080 |
Why?
| | Cell Cycle Checkpoints | 2 | 2019 | 84 | 0.080 |
Why?
| | Polyunsaturated Alkamides | 1 | 2008 | 7 | 0.080 |
Why?
| | Estrogen Receptor Modulators | 1 | 2008 | 17 | 0.080 |
Why?
| | Arachidonic Acids | 1 | 2008 | 56 | 0.080 |
Why?
| | Genetic Association Studies | 1 | 2010 | 339 | 0.080 |
Why?
| | In Vitro Techniques | 1 | 2010 | 1016 | 0.080 |
Why?
| | Hot Flashes | 1 | 2009 | 72 | 0.080 |
Why?
| | Phosphorylation | 1 | 2012 | 1569 | 0.070 |
Why?
| | Oxidants | 1 | 2008 | 112 | 0.070 |
Why?
| | Drug Synergism | 1 | 2008 | 316 | 0.070 |
Why?
| | Polymerase Chain Reaction | 1 | 2010 | 993 | 0.070 |
Why?
| | Heterografts | 2 | 2019 | 117 | 0.070 |
Why?
| | Acetylcysteine | 1 | 2008 | 141 | 0.070 |
Why?
| | Androgens | 1 | 2008 | 167 | 0.070 |
Why?
| | Protein Kinase Inhibitors | 1 | 2012 | 785 | 0.070 |
Why?
| | Cadherins | 2 | 2018 | 175 | 0.070 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2008 | 740 | 0.060 |
Why?
| | Survival Rate | 2 | 2020 | 1644 | 0.060 |
Why?
| | Reactive Oxygen Species | 1 | 2008 | 531 | 0.060 |
Why?
| | Blotting, Western | 1 | 2008 | 1147 | 0.060 |
Why?
| | Patient Compliance | 1 | 2009 | 525 | 0.060 |
Why?
| | Pancreatic Neoplasms | 1 | 2010 | 731 | 0.050 |
Why?
| | Retrospective Studies | 4 | 2021 | 12555 | 0.050 |
Why?
| | Cells, Cultured | 1 | 2010 | 3886 | 0.050 |
Why?
| | Cell Line | 1 | 2008 | 2637 | 0.050 |
Why?
| | Databases, Genetic | 1 | 2023 | 206 | 0.050 |
Why?
| | Follow-Up Studies | 2 | 2020 | 4411 | 0.050 |
Why?
| | Biology | 1 | 2022 | 79 | 0.050 |
Why?
| | Microsurgery | 1 | 2021 | 59 | 0.050 |
Why?
| | Aged | 4 | 2019 | 19074 | 0.040 |
Why?
| | Genetic Predisposition to Disease | 1 | 2009 | 2086 | 0.040 |
Why?
| | Ubiquitination | 1 | 2020 | 86 | 0.040 |
Why?
| | Apoptosis | 2 | 2019 | 2363 | 0.040 |
Why?
| | Proteolysis | 1 | 2020 | 142 | 0.040 |
Why?
| | Movement Disorders | 1 | 2019 | 48 | 0.040 |
Why?
| | Indazoles | 1 | 2019 | 58 | 0.040 |
Why?
| | Oxysterols | 1 | 2018 | 2 | 0.040 |
Why?
| | Fatty Acid Synthase, Type I | 1 | 2018 | 5 | 0.040 |
Why?
| | Adherens Junctions | 1 | 2018 | 26 | 0.040 |
Why?
| | Sterol Regulatory Element Binding Protein 1 | 1 | 2018 | 54 | 0.040 |
Why?
| | DNA Copy Number Variations | 1 | 2019 | 154 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2020 | 399 | 0.040 |
Why?
| | Collagen Type I | 1 | 2018 | 108 | 0.040 |
Why?
| | Adult | 4 | 2021 | 30553 | 0.040 |
Why?
| | Piperidines | 1 | 2019 | 160 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1121 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2019 | 849 | 0.040 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2019 | 167 | 0.040 |
Why?
| | Pharmacogenomic Variants | 1 | 2017 | 33 | 0.040 |
Why?
| | Cell Adhesion | 1 | 2018 | 432 | 0.030 |
Why?
| | Indoles | 1 | 2019 | 304 | 0.030 |
Why?
| | Length of Stay | 1 | 2021 | 962 | 0.030 |
Why?
| | Risk Factors | 2 | 2020 | 8632 | 0.030 |
Why?
| | RNA, Neoplasm | 1 | 2016 | 80 | 0.030 |
Why?
| | DNA, Neoplasm | 1 | 2016 | 157 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2019 | 445 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2017 | 523 | 0.030 |
Why?
| | Mice, SCID | 1 | 2016 | 314 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2017 | 811 | 0.030 |
Why?
| | Extracellular Matrix | 1 | 2018 | 436 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 1796 | 0.030 |
Why?
| | Alleles | 1 | 2017 | 789 | 0.030 |
Why?
| | Male | 3 | 2019 | 55606 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2017 | 698 | 0.030 |
Why?
| | Cell Movement | 1 | 2018 | 869 | 0.030 |
Why?
| | Survival Analysis | 1 | 2017 | 1211 | 0.030 |
Why?
| | Genome | 1 | 2016 | 271 | 0.030 |
Why?
| | Neoplasm Proteins | 1 | 2016 | 385 | 0.030 |
Why?
| | Registries | 1 | 2019 | 1768 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2016 | 1629 | 0.020 |
Why?
| | Disease Progression | 1 | 2018 | 2380 | 0.020 |
Why?
| | Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2010 | 14 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2010 | 182 | 0.020 |
Why?
| | DNA Primers | 1 | 2010 | 510 | 0.020 |
Why?
| | Mice, Nude | 1 | 2010 | 630 | 0.020 |
Why?
| | 8,11,14-Eicosatrienoic Acid | 1 | 2008 | 6 | 0.020 |
Why?
| | Microsomes | 1 | 2008 | 24 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2016 | 2553 | 0.020 |
Why?
| | Hydroxylation | 1 | 2008 | 29 | 0.020 |
Why?
| | Epoxy Compounds | 1 | 2008 | 31 | 0.020 |
Why?
| | Endocannabinoids | 1 | 2008 | 36 | 0.020 |
Why?
| | Arachidonic Acid | 1 | 2008 | 116 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2010 | 1144 | 0.020 |
Why?
| | Base Sequence | 1 | 2010 | 2114 | 0.020 |
Why?
| | Young Adult | 1 | 2019 | 10471 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2017 | 9088 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2010 | 2765 | 0.010 |
Why?
| | Mitochondria | 1 | 2008 | 747 | 0.010 |
Why?
| | Cohort Studies | 1 | 2009 | 4895 | 0.010 |
Why?
| | Time Factors | 1 | 2008 | 6116 | 0.010 |
Why?
| | Prospective Studies | 1 | 2009 | 6220 | 0.010 |
Why?
| | Brain | 1 | 2008 | 2371 | 0.010 |
Why?
|
|
Sikora's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|